About Event

이벤트 소개



Backed by almost 15 years of experience providing insights to the antibody-drug conjugate community, World ADC Asia prides itself in being the definitive industry-led conference uniting the leaders and newcomers of the space to identify and discuss the critical factors that will influence the next 12 months of your ADC development.

There has never been a stronger time for antibody drug conjugate drug development in Asia, with the Japanese-born Enhertu reaching blockbuster status; Asia accounting for half of the new ADC clinical trials in 2023 and surpassing the number of those from the US for 5 years in a row.

Across three packed days, with the highest quality industry speakers, join the likes of Daiichi SankyoEisaiShanghai MiracogenOBI Pharma, Pinotbio, Pfizer, Hummingbird Biosciences, and many others in the APAC region paving the way to innovations. From new approaches to conjugation platforms, tackling challenges within clinical trials of Asian populations, navigating partnering with a CDMO, all with the continued goal of maximizing the therapeutic window of ADCs.

Whether you’re a CEO, Managing Director, head of lab or scientist, this is the meeting for you to get the most up-to-date insight into what’s happening with ADCs in Asia.

Top 5 Reasons to Attend

참석해야 할 5 가지 중요한 이유




Network with likeminded peers in the field facing similar challenges when it comes to language barriers and supply chain sourcing problems in Asia, fostering new relationships to help overcome them and boost ADC development with the likes of Daiichi Sankyo, Genentech, Eisai, Regeneron, Hummingbird Bioscience, and many more


Establish strategic collaborations to enhance communications with mega pharma and improve global rights for development and commercialization with Shanghai Miracogen


Understand the clinical development and ADC landscape in China to analyze the innovation and potential in the region with Gilead


Navigate the challenges of entering of the ADC space as a new company and learn lessons from established ADC developers to increase investment opportunities with Bliss Biopharma


Explore gastrointestinal and novel targets beyond HER2 & TROP2 such as Integrin Beta-6 to lead the charge on ADC innovation with Pfizer